ArticleHuman genetics2026
Association of apolipoprotein E gene with risk, cognition, and prognosis of epilepsy.
Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Previous experimental studies suggested a link between the apolipoprotein E (APOE) gene and epilepsy. However, clinical studies have failed to reach a definitive conclusion on the association. We conducted a cohort study to investigate the clinical correlation between APOE ε4 and epilepsy. This study was based on the UK Biobank. Participants were divided according to the number of APOE ε4 carriers. A Cox proportional hazards model was used to analyse the association between APOE ε4 and the risk of epilepsy, and the association between APOE ε4 and dementia after epilepsy, and the association between APOE ε4 and death. The presence of the APOE ε4 allele was associated with an increased risk of epilepsy, particularly late-onset epilepsy, but the difference in the proportion of APOE ε4 carriers compared with controls in post-stroke epilepsy varied by condition. APOE ε4 carriers were found to have a higher likelihood of dementia following epilepsy onset, with those carrying one copy of the APOE ε4 allele having an approximately 80% higher risk of dementia after epilepsy, and those carrying two copies of the APOE ε4 allele having an approximately 225% higher risk of dementia after epilepsy. APOE ε4 carriers with epilepsy also showed an elevated risk of death, with a trend toward increased risk in those carrying one copy of the APOE ε4 allele and an approximately 39% higher risk of death in those carrying two copies of the APOE ε4 allele. The APOE ε4 allele was associated with an increased risk of epilepsy, particularly late-onset epilepsy among homozygous carriers. Among participants with epilepsy, APOE ε4 carrier status was associated with an increased risk of dementia and premature death, particularly death from neurological causes.
Indexed as
Identifiers
42799898What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.